Comparative Pharmacology
Head-to-head clinical analysis: CATAFLAM versus PONSTEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CATAFLAM versus PONSTEL.
CATAFLAM vs PONSTEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, thereby reducing inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
50 mg orally three times daily; maximum 150 mg/day.
250 mg orally every 6 hours as needed, not to exceed 1 g per day, for no longer than 7 days.
None Documented
None Documented
Terminal elimination half-life of diclofenac is approximately 1-2 hours. However, for the enteric-coated formulation (Cataflam), the half-life may be slightly prolonged due to slower absorption; clinical relevance is minimal as analgesic duration is 4-8 hours.
2-4 hours (terminal elimination half-life); clinical context: duration of analgesia 4-6 hours; accumulates with renal impairment
Approximately 50-60% of a single dose is excreted in urine as metabolites (primarily glucuronide conjugates and 4'-hydroxydiclofenac) with <1% unchanged. 30-40% is excreted in feces via bile. Renal clearance is 250-350 mL/min.
Primarily renal (70-80% as glucuronide conjugates and unchanged drug); biliary/fecal (20-30%)
Category C
Category C
Nonsteroidal Anti-Inflammatory Drug
Nonsteroidal Anti-Inflammatory Drug